Corrigendum to “Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials” volume 72, 102621 (eClinicalMedicine (2024) 72, (S2589537024002001), (10.1016/j.eclinm.2024.102621))

Sudheer K. Vuyyuru, Christopher Ma, Tran M. Nguyen, Guangyong Zou, Laurent Peyrin-Biroulet, Silvio Danese, Parambir Dulai, Neeraj Narula, Siddharth Singh, Vipul Jairath*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the manuscript, the acknowledgements section currently reads “none”. The correct acknowledgement should be “this publication was based on research using data from data contributors Pfizer, AbbVie, and Takeda, that has been made available through Vivli, Inc. Vivli has not contributed to or approved, and is not in any way responsible for the contents of this publication.” The error occurred during the final stages of the manuscript preparation. When we were making final edits and formatting adjustments, the acknowledgements section was inadvertently overlooked The correction of this acknowledgement does not alter the main results or conclusions of the paper. We believe that these changes will more accurately reflect the contributions and support that were instrumental in the completion of our study. We regret our oversight in failing to include this information in the acknowledgements section of this paper.

Original languageEnglish (US)
Article number102980
JournalEClinicalMedicine
Volume78
DOIs
StatePublished - Dec 2024

Funding

CM consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Roche; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Takeda, Pendopharm, and Pfizer; royalties from Springer Publishing; research support from Ferring, Pfizer.

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Corrigendum to “Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials” volume 72, 102621 (eClinicalMedicine (2024) 72, (S2589537024002001), (10.1016/j.eclinm.2024.102621))'. Together they form a unique fingerprint.

Cite this